Pancreatic Cancer
Show Only Open Trials
1.
A Phase 1a/b Non-Randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile Compound 31510 (Ubidecarenone, USP) Nanosuspension for Injection Administered Intravenously to Patients with Solid Tumors
- Study Status: Open to Enrollment
- Sponsor: Berg Pharma
- Disease Status and/or Stage: Advanced Solid Tumors
2.
Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
- Disease Status and/or Stage: Metastatic Epithelial Cancer
3.
A Phase Ib Study of Fractionated 90Y-hPAM4 with or without Gemcitabine in Patients with Metastatic Pancreatic Cancer who Received at Least Two Prior Treatments
- Study Status: Closed to Enrollment
- Sponsor: Immunomedics
- Disease Status and/or Stage: Stage IV Metastatic Pancreatic Cancer
- Protocol ID: IM-T-hPAM4-03
4.
REO 017: A Phase 2 Study of Reolysin® in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
- Study Status: Closed to Enrollment
- Disease Status and/or Stage: Advanced or Metastatic Pancreatic Cancer
5.
A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination with Chemotherapeutic Regimens in Subjects with Advanced Solid Tumors
- Study Status: Closed to Enrollment
- Sponsor: BiPar Sciences
- Disease Status and/or Stage: Metastatic Pancreatic Cancer
6.
A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Solid Tumor
